[1]唐 乾,先正平,唐 钰,等.中药联合化疗治疗中晚期非小细胞肺癌的系统评价和中药有效成分筛选及其机制研究[J].南京师大学报(自然科学版),2025,48(02):47-61.[doi:10.3969/j.issn.1001-4616.2025.02.006]
　Tang Qian,Xian Zhengping,Tang Yu,et al.Systematic Evaluation of Traditional Chinese Medicine Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer and Screening of Effective Components of Traditional Chinese Medicine and Its Mechanism[J].Journal of Nanjing Normal University(Natural Science Edition),2025,48(02):47-61.[doi:10.3969/j.issn.1001-4616.2025.02.006]
点击复制

中药联合化疗治疗中晚期非小细胞肺癌的系统评价和中药有效成分筛选及其机制研究()

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

卷:
48
期数:
2025年02期
页码:
47-61
栏目:
生物学
出版日期:
2025-04-15

文章信息/Info

Title:
Systematic Evaluation of Traditional Chinese Medicine Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer and Screening of Effective Components of Traditional Chinese Medicine and Its Mechanism
文章编号:
1001-4616(2025)02-0047-15
作者:
唐 乾1; 2; 先正平1; 唐 钰1; 曹洪玉1; 2; 王立皓2; 3; 佟昊聪2; 杜亚男2; 郑学仿2; 3
(1.大连大学生命健康学院,辽宁 大连 116622)
(2.大连大学环境与化学工程学院,辽宁 大连 116622)
(3.辽宁省生物有机化学重点实验室,大连大学,辽宁 大连 116622)
Author(s):
Tang Qian1; 2; Xian Zhengping1; Tang Yu1; Cao Hongyu1; 2; Wang Lihao2; 3; Tong Haocong2; Du Yanan2; Zheng Xuefang2; 3
(1.College of Life and Healthy,Dalian University,Dalian 116622,China)
(2.College of Environmental and Chemical Engineering,Dalian University,Dalian 116622,China)
(3.Liaoning Key Laboratory of Bio-organic Chemistry,Dalian University,Dalian 116622,China)
关键词:
非小细胞肺癌; 中药; Meta分析; 用药规律; 网络药理学; 分子对接; 生物学验证
Keywords:
non-small cell lung cancer; Chinese medicine; Meta-analysis; compatibility rules; network pharmacology; molecular docking; biological validation
分类号:
O641; O622; R273
DOI:
10.3969/j.issn.1001-4616.2025.02.006
文献标志码:
A
摘要:
中药不论在直接抑制肿瘤生长,还是辅助西医治疗肿瘤方面都发挥着不容忽视的作用. 本文经检索中国知网、万方、维普、Pubmed、Web of Science等数据库,纳入中药汤剂联合化疗治疗非小细胞肺癌(NSCLC)的随机对照试验,通过Meta、用药规律、网络药理学和细胞实验等分析方法系统评价中药联合化疗治疗NSCLC的疗效、安全性及作用机制,最终纳入56篇文献进行统计分析,共4 992例患者、57首处方、172味中药. 结果显示,中药联合化疗治疗组的1年生存率、肝功能损伤、总有效率、胃肠道不良反应等方面均优于单纯化疗组. 用药频次>20的有7味:药味以甘苦为主,药性以寒温为主,主要归为肺经和肝经. 得到5个高频药物聚类,关联规则分析得到置信度最高的4条药物组合为:天花粉-麦冬、玉竹-麦冬、北沙参-玉竹-麦冬、白术-黄芪-党参. 收集到核心中药成分潜在作用靶点与NSCLC交集靶点126个; PPI分析得到3个核心靶点:AKT1、EGFR、SRC; KEGG分析表明关键通路为PI3K-Akt信号通路; 筛选得到3个关键成分:木犀草素、槲皮素、山柰酚; 分子对接结果表明关键成分和核心靶点均能稳定结合. 细胞实验结果表明,木犀草素可有效抑制A549细胞的增殖、活力和迁移,诱导其发生凋亡,并使其形态发生变化. 本文结果表明,中药联合化疗治疗NSCLC可以提高其临床疗效、降低化疗的毒副作用; 黄芪、麦冬、党参、北沙参等核心中药多种成分可通过多靶点、多途径协同治疗NSCLC; 关键中药的核心成分木犀草素可抑制A549细胞的增殖、活力和迁移,并可诱导其发生凋亡.
Abstract:
Traditional Chinese medicine plays an important role in both directly inhibiting tumor growth and assisting western medicine in the treatment of tumors. In this paper,the study searched CNKI,Wanfang,VIP,Pubmed,Web of Science and other databases to include randomized controlled trials of traditional Chinese medicine decoction combined with chemotherapy in the treatment of NSCLC. The efficacy,safety and mechanism of traditional Chinese medicine combined with chemotherapy in the treatment of non-small cell lung cancer(NSCLC)were systematically evaluated by Meta,medication rules,network pharmacology and cell experiments. The efficacy,safety and mechanism of traditional Chinese medicine combined with chemotherapy in the treatment of non-small cell lung cancer were systematically evaluated by Meta,medication rules,network pharmacology and other analytical methods. Finally,56 articles were included for statistical analysis,a total of 4992 patients,57 prescriptions,and 172 Chinese medicines. The results showed that the total effective rate,liver function injury,gastrointestinal reaction and 1-year survival rate of the combined treatment group were better than those of the chemotherapy group. There were 7 flavors with medication frequency>20,the flavor of the medicine was mainly sweet and bitter,the medicinal properties were mainly cold and warm,mainly classified as lung meridian and liver meridian,5 high-frequency drug clusters were obtained,4 drug combinations with the highest confidence obtained by association rule analysis,that were Trichosanthis Radix-Ophiopogon japonicus,Polygonatum odoratum-Ophiopogon japonicus,Glehniae Radix-Polygonatum odoratum-Ophiopogon japonicus,Atractylodes-Astragali Radix-Codonopsis Radix. A total of 126 potential targets of core Chinese medicine components and NSCLC intersection targets were collected. Three core targets were obtained by PPI analysis:AKT1,EGFR and SRC. KEGG analysis showed that the key pathway was PI3K-Akt signaling pathway. Three key components were screened,that were luteolin,quercetin and kaempferol,the results of molecular docking showed that the key components and core targets could be stably combined. The results of cell experiments showed that luteolin could effectively inhibit the proliferation,viability and migration of A549 cells,induce apoptosis and change their morphology. The results of this paper showed that traditional Chinese medicine combined with chemotherapy in the treatment of NSCLC could improve its clinical efficacy and reduce the toxic and side effects of chemotherapy. Astragali Radix,Ophiopogon japonicus,Codonopsis Radix,Glehniae Radix and other core components of traditional Chinese medicine can treat NSCLC through multi-target and multi-channel synergy,luteolin can inhibit the proliferation,viability and migration of A549 cells,and induce their apoptosis.

参考文献/References:

[1]SIEGEL R L,MILLER K D,FUCHS H E,et al. Cancer statistics[J]. CA-A cancer journal for clinicians,2021,71(1):7-33.
[2]ZHENG R,ZHANG S,ZENG H,et al. Cancer incidence and mortality in China[J]. Journal of the national cancer center,2022,2(1):1-9.
[3]SUN D,LI H,CAO M,et al. Cancer burden in China:trends,risk factors and prevention[J]. Cancer biology & medicine,2020,17(4):879-895.
[4]TRAVIS W D,BRAMBILLA E,NICHOLSON A G,et al. The 2015 World Health Organization classification of lung tumors:impact of genetic,clinical and radiologic advances since the 2004 classification[J]. Journal of thoracic oncology,2015,10(9):1243-1260.
[5]ST C S,GOUDA H,SCHOTTE K,et al. Lung health,tobacco,and related products:gaps,challenges,new threats,and suggested research[J]. American journal of physiology:lung cellular and molecular physiology,2020,318(5):L1004-L1007.
[6]UPADHYA A,YADAV K S,MISRA A. Targeted drug therapy in non-small cell lung cancer:Clinical significance and possible solutions-Part I[J]. Expert opinion on drug delivery,2021,18(1):73-102.
[7]ROCCO D,GREGORC V,DELLA G L,et al. New immunotherapeutic drugs in advanced non-small cell lung cancer(NSCLC):from preclinical to phase I clinical trials[J]. Expert opinion on investigational drugs,2020,29(9):1005-1023.
[8]REN L,MO W,WANG L,et al. Matrine suppresses breast cancer metastasis by targeting ITGB1 and inhibiting epithelial to mesenchymal transition[J]. Experimental and therapeutic medicine,2020,19(1):367-374.
[9]GAI P,LI N,LIU M. Effect of combining traditional Chinese medicine with hormonal therapy on quality of life and tumor markers of prostate cancer patients[J]. Evidence based complementary alternative medicine,2021,2021:5061867.
[10]MENG W,ZENG X,GAO Y,et al. Efficacy of aidi injection and brucea javanica oil emulsion injection in rectal cancer during CapeOX adjuvant chemotherapy[J]. Biomed research international,2021,2021:2033353.
[11]国家药典委员会. 中华人民共和国药典[M]. 北京:中国医药科技出版社,2020.
[12]JIMÉNEZ J,DOERR S,MARTÍNEZ-ROSELL G,et al. DeepSite:protein-binding site predictor using 3D-convolutional neural networks[J]. Bioinformatics,2017,33(19):3036-3042.
[13]安君君. 培土生金汤联合化疗治疗肺脾气虚型中晚期非小细胞肺癌患者的临床研究[D]. 郑州:河南中医药大学,2019.
[14]曾省都,陈红,刘春花. 扶正消癥汤联合化疗治疗晚期非小细胞肺癌的临床研究[J]. 江西医药,2022,57(10):1370-1373.
[15]陈创,王秀改,刘振昌. 益肺解毒汤对晚期非小细胞肺癌患者TP化疗方案的增效减毒作用研究[J]. 实用心脑肺血管病杂志,2018,26(8):61-65.
[16]陈皎皎,白平,彭爽,等. 清肺化积汤配合化疗对非小细胞肺癌患者免疫功能及血清MMP-9水平的影响研究[J]. 四川中医,2018,36(7):102-105.
[17]陈艳,孙连庆,胡粒山. 六君子汤加减对晚期非小细胞肺癌GP方案肺脾气虚型患者的作用机制研究[J]. 西部中医药,2022,35(1):119-123.
[18]程伟,邢东炜. 益气养阴汤联合化疗一线药物治疗晚期非小细胞肺癌的临床观察[J]. 中药材,2020,43(10):2565-2568.
[19]邓海滨,王中奇,吴继,等. 抗瘤增效方结合化疗治疗中晚期非小细胞肺癌97例[J]. 上海中医药杂志,2014,48(4):32-35.
[20]董红兵. 参芪蛇枝汤联合GP方案治疗中晚期非小细胞肺癌临床研究[J]. 中医学报,2016,31(12):1849-1851.
[21]冯凯雯. 晚期NSCLC患者应用自拟扶正解毒宣肺方配合GP化疗方案对患者无进展生存期的影响[J]. 医学理论与实践,2020,33(21):3516-3518.
[22]龚敏杰. 沙参麦冬汤加减联合化疗治疗非小细胞肺癌的疗效及安全性评价[J]. 养生大世界,2021,20(21):147-148.
[23]何玲,郭成龙,裴正学. 中医辨证分型联合化疗治疗晚期非小细胞肺癌50例疗效观察[J]. 国医论坛,2019,34(4):40-42.
[24]黄唤芝. 参芪四物汤加减联合化疗对肺癌肺脾两虚证临床疗效观察[D]. 长沙:湖南中医药大学,2021.
[25]加依娜·铁木尔汗,梁振玺. 中医辨证分型联合化疗在中晚期非小细胞肺癌治疗中的临床观察[J]. 光明中医,2018,33(21):3232-3233.
[26]蒋锦玉. 清金抑瘤汤治疗中晚期非小细胞肺癌患者临床疗效及对血清IL-2、IL-10的影响[D]. 长沙:湖南省中医药研究院; 湖南中医药大学,2008.
[27]孔凯凯. 补肺化瘀汤结合一线化疗方案治疗非小细胞肺癌的疗效观察[J]. 现代诊断与治疗,2020,31(9):1362-1364.
[28]李德辉,孙春霞,范焕芳. 六君子汤加减辅助晚期非小细胞肺癌化疗的临床观察[J]. 中国药房,2017,28(36):5068-5071.
[29]李涵,姬广辉,郭立杰. 八珍汤加减辅助化疗治疗晚期非小细胞肺癌的临床疗效及对化疗不良反应的影响研究[J]. 世界中医药,2018,13(9):2207-2210,2215.
[30]李政,王巍,李康. 葶苈甘遂逐水饮联合胸腔内灌注化疗治疗晚期非小细胞肺癌伴恶性胸水临床疗效分析[J]. 辽宁中医药大学学报,2016,18(1):198-200.
[31]刘创健,李竹英. 益气清热养阴法治疗晚期肺癌的临床疗效与免疫调节作用观察[J]. 中医药学报,2012,40(3):182-184.
[32]刘杰. 健脾化痰祛湿方联合DP方案治疗脾虚痰湿型晚期非小细胞肺癌的临床研究[D]. 南京:南京中医药大学,2017.
[33]刘丽梅,赖红华. 四君子汤合沙参麦冬汤加减治疗中晚期非小细胞肺癌160例[J]. 环球中医药,2018,11(1):123-126.
[34]刘明,吴艳丽,曾荣. 沙参麦冬汤加减联合化疗治疗非小细胞肺癌效果观察[J]. 临床合理用药杂志,2020,13(11):53-54.
[35]刘英雄,徐复娟,徐宝秋,等. 益气养阴解毒方治疗Ⅳ期非小细胞肺癌临床研究[J]. 新中医,2021,53(6):89-92.
[36]卢言琪,孟启明,陈玉英,等. 参芪解毒汤辅助治疗晚期非小细胞肺癌的疗效[J]. 世界中医药,2021,16(7):1113-1117.
[37]陆青媛,武国生. 四君子汤合沙参麦冬汤加减对中晚期NSCLC的临床观察[J]. 光明中医,2020,35(10):1513-1516.
[38]陆群英,刘俊波,杨红伟,等. 清肺散结汤配合化疗治疗晚期非小细胞肺癌30例临床疗效观察[J]. 中医临床研究,2016,8(24):130-133.
[39]陆烨,王晨洁,余蓉. 生脉饮加味联合化疗治疗晚期非小细胞肺癌临床研究[J]. 中医学报,2014,29(10):1400-1402.
[40]吕娅萍,李春,潘新有,等. 补中益气汤合沙参麦冬汤加减联合化疗治疗非小细胞肺癌临床疗效观察[J]. 现代诊断与治疗,2017,28(15):2773-2775.
[41]吕振选,田国防,李春青,等. 补中益气汤、沙参麦冬汤加减、化疗三联治疗非小细胞肺癌的临床疗效观察[J]. 中国民康医学,2018,30(7):80-82.
[42]宋伟祥,刘玉金,李浏博. “清肺消积方”配合介入化疗治疗老年晚期肺癌30例临床研究[J]. 江苏中医药,2018,50(4):34-37.
[43]苏继红,王姣姣,张大明. 益气养精汤联合吉西他滨和顺铂化疗对中晚期肺癌的疗效观察[J]. 中国肿瘤临床与康复,2020,27(5):564-567.
[44]苏田. 扶正培元汤联合NP化疗方案治疗晚期NSCLC疗效及对血清IFN-γ、TGF-β和IL-10的影响[J]. 国际医药卫生导报,2020,26(20):3059-3061.
[45]孙佩佩,綦丰光,张颖颖,等. 麦门冬汤合苇茎汤加减治疗肺癌化疗患者的临床观察[J]. 世界中医药,2020,15(13):1967-1971.
[46]童玫瑰,查名宝,许林利. 养阴清热方联合含铂类化疗方案治疗晚期非小细胞肺癌的疗效分析[J]. 癌症进展,2019,17(21):2516-2519.
[47]王爱帅. 加味芪莲合剂治疗晚期NSCLC临床观察及黄芪甲苷抗肿瘤免疫机制研究[D]. 济南:山东中医药大学,2020.
[48]王碧娟,葛巧. 中西医结合治疗非小细胞肺癌临床观察[J]. 新中医,2016,48(10):163-165.
[49]王东建. 益气养阴中药联合化疗对晚期非小细胞肺癌的疗效观察[J]. 现代医学与健康研究电子杂志,2019,3(16):80-81.
[50]王惠霞. 益气养阴汤辅助培美曲塞联合顺铂化疗方案治疗非小细胞肺癌的临床效果[J]. 河南医学研究,2021,30(11):2072-2074.
[51]王恺晨,柳正植,彭煜,等. 参赭镇气汤联合顺铂和培美曲塞对晚期非小细胞肺癌患者的临床疗效[J]. 中成药,2022,44(3):785-789.
[52]王瑞丽. 化疗联合健脾补肺汤治疗晚期非小细胞肺癌的疗效及对患者毒副反应、生存质量的影响[J]. 中医临床研究,2016,8(19):68-71.
[53]王秀改,刘振昌,陈创. 益气养阴法联合含铂化疗方案治疗中晚期NSCLC患者的临床疗效及对免疫功能、VEGF、IL-6和MMP-9水平的影响[J]. 四川中医,2021,39(12):88-91.
[54]王颜. 补肺化瘀汤治疗晚期非小细胞肺癌的效果及对血清CA125、EGFR表达的影响[J]. 医学理论与实践,2021,34(15):2624-2625.
[55]武宜婷,渠景连,郭楠楠,等. 补阳还五汤联合GP化疗方案治疗晚期非小细胞肺癌的临床效果[J]. 中国医药导报,2018,15(36):113-116.
[56]肖彦. 健脾益肾、化瘀散结法配合紫杉醇脂质体治疗老年非小细胞肺癌的临床观察[D]. 长沙:湖南中医药大学,2015.
[57]谢英瑛,徐溶慧. 沙参麦冬汤联合化疗治疗中晚期非小细胞肺癌的效果及对患者免疫功能的影响[J]. 临床医学研究与实践,2021,6(26):137-139.
[58]徐聂,肖敏伟,罗婷,等. 八珍汤辅助化疗治疗老年晚期非小细胞肺癌的临床效果[J]. 临床医学研究与实践,2021,6(19):128-129.
[59]许诺,张祺箐,冯正权. 沙参麦冬汤加味方联合化疗对阴虚毒热证非小细胞肺癌患者的影响[J]. 广州中医药大学学报,2021,38(1):21-26.
[60]严小萍,杨杰,沈爱云. 清肺消瘤汤内服联合化疗治疗中晚期非小细胞肺癌的临床研究[J]. 现代中西医结合杂志,2016,25(3):284-286.
[61]杨清乐. 养金护肺汤联合GP方案治疗气阴两虚型中晚期NSCLC患者临床观察[D]. 郑州:河南中医药大学,2016.
[62]姚衡,姚德蛟. 血府逐瘀汤加减联合化疗治疗气滞血瘀型中晚期非小细胞肺癌45例[J]. 湖南中医杂志,2021,37(11):57-60.
[63]袁慧洁,杨国亮. 自拟养肺抗癌方联合一线化疗方案治疗晚期非小细胞肺癌的临床研究[J]. 现代中西医结合杂志,2020,29(9):972-975.
[64]袁坤. 固肺消积饮联合支气管动脉化疗灌注治疗对老年局部晚期非小细胞肺癌的临床研究[D]. 长沙:湖南中医药大学,2020.
[65]张成. 祛毒扶正汤联合化疗治疗中晚期非小细胞肺癌的疗效及对患者癌因性疲乏、化疗耐受性的影响[J]. 四川中医,2019,37(1):107-109.
[66]张梦馨,祝云鹤,白月琴,等. 培元抗癌汤联合NP化疗方案治疗晚期非小细胞肺癌疗效及对血清肿瘤标志物和免疫功能的影响[J]. 现代中西医结合杂志,2022,31(15):2108-2111.
[67]赵美随. 金福安汤联合TP方案治疗对Ⅲ、Ⅳ期非小细胞肺癌脾虚痰湿型患者中医症候积分、生存质量及血清CEA、CY211水平的影响[J]. 四川中医,2018,36(7):105-108.
[68]周婷婷. 扶正抗癌方联合化疗治疗晚期非小细胞肺癌的临床疗效观察及其抗肿瘤机制的研究[D]. 扬州:扬州大学,2019.
[69]郑威,黄杰. 胸腔镜肺叶切除术对非小细胞肺癌患者炎性因子及免疫功能的影响[J]. 实用癌症杂志,2017,32(2):295-298.
[70]欧阳怡然,李和根. 化疗联合中药对非小细胞肺癌术后辅助治疗作用的研究进展[J]. 湖南中医杂志,2018,34(4):172-176.
[71]张晋韬,吴万垠. 紫龙金片治疗老年非小细胞肺癌的真实世界疗效分析[J]. 中草药,2022,53(22):7177-7182.
[72]TAO X,ZHANG X,FENG F. Astragalus polysaccharide suppresses cell proliferation and invasion by up-regulation of mir-195-5p in non-small cell lung cancer[J]. Biological & pharamaceutical bulletin,2022,45(5):553-560.
[73]CHEN M,LI Y,LIU Z,et al. Exopolysaccharides from a Codonopsis pilosula endophyte activate macrophages and inhibit cancer cell proliferation and migration[J]. Thoracic cancer,2018,9(5):630-639.
[74]WU J,GAO W,SONG Z,et al. Anticancer activity of polysaccharide from Glehnia littoralis on human lung cancer cell line A549[J]. International journal of biological macromolecules,2018,106:464-472.
[75]CHENG Z,LI Z,GU L,et al. Ophiopogonin B alleviates cisplatin resistance of lung cancer cells by inducing Caspase-1/GSDMD dependent pyroptosis[J]. Journal of cancer,2022,13(2):715-727.
[76]TANDON M,VEMULA S V,MITTAL S K. Emerging strategies for EphA2 receptor targeting for cancer therapeutics[J]. Expert opinion on therapeutic targets,2011,15(1):31-51.
[77]CHEN M,HU C,GUO Y,et al. Ophiopogonin B suppresses the metastasis and angiogenesis of A549 cells in vitro and in vivo by inhibiting the EphA2/Akt signaling pathway[J]. Oncology reports,2018,40(3):1339-1347.
[78]JIA L,LV D,ZHANG S,et al. Astragaloside IV inhibits the progression of non-small cell lung cancer through the Akt/GSK-3β/β-Catenin pathway[J]. Oncology research,2019,27(4):503-508.
[79]LUAN Y P,LI Q F,WU S G,et al. Tsoong induces apoptosis and inhibits proliferation,migration and invasion of pancreatic ductal adenocarcinoma cells[J]. Molecular medicine reports,2018,17(3):3527-3536.
[80]PAN J,CAI X,ZHENG X,et al. Luteolin inhibits viability,migration,angiogenesis and invasion of non-small cell lung cancer vascular endothelial cells via miR-133a-3p/purine rich element binding protein B-mediated MAPK and PI3K/Akt signaling pathways[J]. Tissue cell,2022,75:101740.
[81]WANG Y,CHEN X,LI J,et al. Quercetin antagonizes esophagus cancer by modulating miR-1-3p/TAGLN2 pathway-dependent growth and metastasis[J]. Nutrition and cancer,2022,74(5):1872-1881.
[82]QIU W,LIN J,ZHU Y,et al. Kaempferol modulates DNA methylation and downregulates DNMT3B in bladder cancer[J]. Cellular physiology and biochemistry,2017,41(4):1325-1335.
[83]BAHRAMI A,KHAZAEI M,HASANZADEH M,et al. Therapeutic potential of targeting PI3K/AKT pathway in treatment of colorectal cancer:rational and progress[J]. Journal of cellular biochemistry,2018,119(3):2460-2469.
[84]HU B,QIN C,LI L,et al. Midkine promotes glioblastoma progression via PI3K-Akt signaling[J]. Cancer cell international,2021,21(1):509.
[85]SHORNING B Y,DASS M S,SMALLEY M J,et al. The PI3K-AKT-mTOR pathway and prostate cancer:At the crossroads of AR,MAPK,and WNT signaling[J]. International journal of molecular sciences,2020,21(12):4507.
[86]PANG X,ZHOU Z,YU Z,et al. Foxo3a-dependent miR-633 regulates chemotherapeutic sensitivity in gastric cancer by targeting Fas-associated death domain[J]. RNA biology,2019,16(2):233-248.
[87]TIWARI V,KAMRAN M Z,RANJAN A,et al. Akt1/NFκB signaling pathway activation by a small molecule DMA confers radioprotection to intestinal epithelium in xenograft model[J]. Free radicical biology and medicine,2017,108:564-574.
[88]ADIL M S,KHULOOD D,SOMANATH P R. Targeting Akt-associated microRNAs for cancer therapeutics[J]. Biochem pharmacol,2021,189:114384.
[89]PENE F,CLAESSENS Y E,MULLER O,et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma[J]. Oncogene,2002,21(43):6587-6597.
[90]LI S J,SUN S J,GAO J,et al. Wogonin induces Beclin-1/PI3K and reactive oxygen species-mediated autophagy in human pancreatic cancer cells[J]. Oncology letters,2016,12(6):5059-5067.
[91]张仙宏,魏萌萌,袁冬冬,等. 转录因子FOXOs家族调控肿瘤生物学功能的研究进展[J]. 生理学报,2022,74(5):843-855.
[92]EIJKELENBOOM A,BURGERING B M. FOXOs:signalling integrators for homeostasis maintenance[J]. Nature reviews molecular cell biology,2013,14(2):83-97.
[93]YAJIE D,FENG L,ZHAOYAN LI,et al. Efficacy of luteolin on the human gastric cancer cell line MKN45 and underlying mechanism[J]. Journal of traditional Chinese medicine,2023,43(1):34-41.
[94]KRIFA M,LELOUP L,GHEDIRA K,et al. Luteolin induces apoptosis in BE colorectal cancer cells by downregulating calpain,UHRF1,and DNMT1 expressions[J]. Nutrition and cancer,2014,66(7):1220-1227.
[95]PAN J,CAI X,ZHENG X,et al. Luteolin inhibits viability,migration,angiogenesis and invasion of non-small cell lung cancer vascular endothelial cells via miR-133a-3p/purine rich element binding protein B-mediated MAPK and PI3K/Akt signaling pathways[J]. Tissue cell,2022,75:101740.
[96]ÖZERKAN D. The determination of cisplatin and luteolin synergistic effect on colorectal cancer cell apoptosis and mitochondrial dysfunction by fluorescence labelling[J]. Journal of fluorescence,2023,33(3):1217-1225.
[97]ZHENG Y,LI L,CHEN H,et al. Luteolin exhibits synergistic therapeutic efficacy with erastin to induce ferroptosis in colon cancer cells through the HIC1-mediated inhibition of GPX4 expression[J]. Free radicical biology medicine,2023,208:530-544.
[98]WU B,ZHANG Q,SHEN W,et al. Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line[J]. Molecular and cellular biochemistry,2008,313(1/2):125-132.
[99]WU H T,LIN J,LIU Y E,et al. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway[J]. Phytomedicine,2021,81:153437.
[100]YOO H S,WON S B,KWON Y H. Luteolin induces apoptosis and autophagy in HCT116 colon cancer cells via p53-dependent pathway[J]. Nutrition and cancer,2022,74(2):677-686.

相似文献/References:

[1]李 敏,谌 茜,马 倬,等.eIF4E 在非小细胞肺癌耐药性中的作用[J].南京师大学报(自然科学版),2014,37(02):91.
　Li Min,Chen Xi,Ma Zhuo,et al.eIF4E Promotes Drug Resistance in Non-small Cell Lung Carcinoma[J].Journal of Nanjing Normal University(Natural Science Edition),2014,37(02):91.

备注/Memo

备注/Memo:
收稿日期:2023-12-15.
基金项目:国家自然科学基金项目(21571025、21601024、21601025、21601023)、大连大学学科建设专项-学科交叉项目(DLUXK-2023-YB-007)、大连大学学科平台项目(202101ZD01).
通讯作者:郑学仿,博士,教授,研究方向:生物无机化学,药物分子设计,计算化学. E-mail:dlxfzheng@126.com
更新日期/Last Update: 2025-04-15